ClinicaliQ Trial Snapshot
- A Study to Evaluate ALN-4285 in Adult Healthy Volunteers — Recruiting • Phase I • NCT07295717.
- ALN-4285 safety, tolerability, and how the body processes single doses tested in healthy adults.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to: * evaluate the safety and tolerability of single ascending doses of ALN-4285 in healthy volunteers * characterize the single-dose pharmacokinetics (PK) of ALN-4285 Conditions: Healthy Volunteers Interventions: ALN-4285, Placebo Lead Sponsor: Alnylam Pharmaceuticals Planned Enrollment: 76 participants